Genprex (NASDAQ: GNPX), a clinical-stage, gene-therapy
company, recently announced that it has retained pharmaceutical branding agency
Addison Whitney to assist with the naming of the company’s leading drug
candidate (http://ibn.fm/ci3KJ).
An article further discussing the company reads, “Addison Whitney has a proven
track record of branding success within the pharmaceutical market. It enables
clients to achieve growth through both brand differentiation and creative
naming practices. Its most recent successes include guiding pharmaceutical
companies such as Merck, Celgene and Roche through the regulatory steps needed for
name approval. . . . According to Genprex Chairman and CEO Rodney Varner,
retaining the services of Addison Whitney is an important step in bringing
Oncoprex to market. Obtaining regulatory approval for the proprietary and
non-proprietary drug names is one of the essentials for securing market
approval, he explained. Varner said that he believes that Addison Whitney has
an excellent reputation when it comes to securing such name approvals.”
To view the full article, visit http://ibn.fm/8zRMK
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex immunogene therapy for non-small cell lung cancer.
Genprex’s platform technologies are designed to administer cancer-fighting
genes by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities. Oncoprex has
a multimodal mechanism of action whereby it interrupts cell-signaling pathways
that cause replication and proliferation of cancer cells; re-establishes
pathways for apoptosis, or programmed cell death, in cancer cell;, and
modulates the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. For more information,
visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
